Wedbush Downgrades Zentalis Pharmaceuticals (ZNTL) to Neutral
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $3.56 -14.22%
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush analyst Robert Driscoll downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Outperform to Neutral with a price target of $12.00 (from $38.00).
For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.
Shares of Zentalis Pharmaceuticals closed at $10.20 yesterday.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
- Travel Food Services (TRAVELFO:IN) PT Raised to INR1,600 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
